These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28202824)

  • 41. Immunologic treatment of Parkinson's disease.
    Jankovic J
    Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
    [No Abstract]   [Full Text] [Related]  

  • 42. Old and new challenges in Parkinson's disease therapeutics.
    Pires AO; Teixeira FG; Mendes-Pinheiro B; Serra SC; Sousa N; Salgado AJ
    Prog Neurobiol; 2017 Sep; 156():69-89. PubMed ID: 28457671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 85-year old man with Parkinson's disease accompanying dementia.
    Sakatu M
    Brain Nerve; 2010 Jun; 62(6):635-42. PubMed ID: 20593577
    [No Abstract]   [Full Text] [Related]  

  • 44. Controversies over the staging of alpha-synuclein pathology in Parkinson's disease.
    Kalaitzakis ME; Graeber MB; Gentleman SM; Pearce RK
    Acta Neuropathol; 2008 Jul; 116(1):125-8; author reply 129-31. PubMed ID: 18446352
    [No Abstract]   [Full Text] [Related]  

  • 45. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD.
    Kalia LV; Lang AE
    Nat Rev Neurol; 2016 Feb; 12(2):65-6. PubMed ID: 26782330
    [No Abstract]   [Full Text] [Related]  

  • 47. Viral vectors, animal models and new therapies for Parkinson's disease.
    Schneider B; Zufferey R; Aebischer P
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S169-71. PubMed ID: 18585946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease.
    Bellucci A; Zaltieri M; Navarria L; Grigoletto J; Missale C; Spano P
    Brain Res; 2012 Oct; 1476():183-202. PubMed ID: 22560500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?
    Goldberg MS; Lansbury PT
    Nat Cell Biol; 2000 Jul; 2(7):E115-9. PubMed ID: 10878819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease.
    Hilton D; Stephens M; Kirk L; Edwards P; Potter R; Zajicek J; Broughton E; Hagan H; Carroll C
    Acta Neuropathol; 2014 Feb; 127(2):235-41. PubMed ID: 24240814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.
    Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA
    Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A 73-year-old woman with familial Parkinson's disease].
    Takanashi M; Urabe T; Ohta S; Hamano Y; Mori H; Shirai T; Kondo T; Mizuno Y
    No To Shinkei; 1999 Dec; 51(12):1087-96. PubMed ID: 10654309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can Parkinson's disease pathology be propagated from one neuron to another?
    Dunning CJ; Reyes JF; Steiner JA; Brundin P
    Prog Neurobiol; 2012 May; 97(2):205-19. PubMed ID: 22115849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters.
    Chistiakov DA; Chistiakov AA
    Acta Neurol Belg; 2017 Mar; 117(1):43-51. PubMed ID: 27473175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Interaction of Alpha-synuclein with Membranes and its Implication in Parkinson's Disease: A Literature Review.
    Gonzalez-Horta A
    Nat Prod Commun; 2015 Oct; 10(10):1775-8. PubMed ID: 26669123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parkinson's disease and other alpha-synucleinopathies.
    Goedert M
    Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Personalized treatment of Parkinson's disease].
    Brockmann K; Gasser T
    Nervenarzt; 2019 Aug; 90(8):767-772. PubMed ID: 31243506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
    Li B; Zhang Y; Yuan Y; Chen N
    Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Animal models of neurodegenerative diseases.
    Phillips W; Michell A; Pruess H; Barker RA
    Methods Mol Biol; 2009; 549():137-55. PubMed ID: 19378201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.